Document And Entity Information [Abstract] Document Type Document Quarterly Report Document Period End Date Document Transition Report Entity File Number Entity Registrant Name Entity Incorporation, State or Country Code Entity Tax Identification Number Entity Address, Address Line One Entity Address, City or Town Entity Address, State or Province Entity Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Entity Current Reporting Status Entity Interactive Data Current 1 Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Entity Shell Company Entity Common Stock, Shares Outstanding Entity Central Index Key Current Fiscal Year End Date Document Fiscal Year Focus Document Fiscal Period Focus Amendment Flag Condensed Consolidated Balance Sheets Assets Current assets: Cash and cash equivalents Short-term investment securities Receivables, Net, Current Accounts receivable, net Inventory, Net Inventories Total Inventory Sum of the amounts paid in advance for capitalized costs that will be expensed with Research and development. Prepaid research and development Other current assets Assets, Current Total current assets Restricted Cash, Noncurrent Restricted cash Long-term Investments Long-term investment securities Operating Lease, Right-of-Use Asset Right of use assets Leasehold interest, net Equipment, net Goodwill Assets [Default Label] Total assets Liabilities and stockholders' equity Current liabilities: Accounts payable and accrued expenses Other Liabilities, Current Other current liabilities Operating Lease, Liability, Current Lease liability - current portion Lease liability current portion Accrued compensation Liabilities, Current Total current liabilities Deferred revenue, net of current portion Long-term Debt, Excluding Current Maturities Loan payable - non-current Loan payable non-current Operating Lease, Liability, Noncurrent Lease liability - non-current Lease liability non-current Liabilities Total liabilities Commitments and contingencies. Commitments and contingencies Stockholders' equity: Common stock, $0.001 par value per share (150,000,000 shares authorized, 110,209,293 and 109,425,243 shares issued, 110,167,984 and 109,383,934 shares outstanding at March 31, 2020 and December 31, 2019, respectively) Common stock, $0.001 par value per share (175,000,000 shares authorized, 150,969,323 and 146,426,697 shares issued, 150,928,014 and 146,385,388 shares outstanding at June 30, 2023 and December 31, 2022, respectively) Additional paid-in capital Treasury Stock, Common, Value Treasury stock, at cost, 41,309 shares at June 30, 2023 and December 31, 2022 Accumulated deficit Accumulated deficit Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Balance Balance Total stockholders' equity Liabilities and Equity Total liabilities and stockholders' equity Common stock, par value Common stock, par value (in dollars per share) Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Treasury Stock, Common, Shares Treasury stock, balance (in shares) Treasury stock, balance (in shares) Treasury stock, shares Condensed Consolidated Statements of Operations Statement [Table] Product and Service [Axis] Product and Service [Domain] Product revenue, net [Member] License revenue [Member] Statement [Line Items] Revenue: Revenue from Contract with Customer, Excluding Assessed Tax Revenue Costs and expenses: The aggregate cost of product revenue during the reporting period. Cost of Product Revenue Cost of product revenue Research and development: The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to research and development expenses during the reporting period. Noncash compensation Other research and development Other research and development Research and Development Expense Total research and development Selling, General and Administrative Expense [Abstract] Selling, general and administrative: The aggregate compensation expense related to the grants of stock options and restricted stock that is attributable to selling general and administrative expenses during the reporting period. Non Cash Compensation Selling General And Administrative Expenses Noncash compensation Other Selling, General and Administrative Expense Other selling, general and administrative Selling, General and Administrative Expense Total selling, general and administrative Total costs and expenses Total costs and expenses Operating Income (Loss) Operating loss Other (income) expense: Other expense (income): Interest Expense Interest expense Other Income Other income Nonoperating Income (Expense) Total other expense (income), net Net loss Net loss Net loss Earnings Per Share, Basic Basic net loss per common share (in dollars per share) Earnings Per Share, Diluted Diluted net loss per common share (in dollars per share) Weighted Average Number of Shares Outstanding, Basic Weighted-average shares used in computing basic net loss per common share (in shares) Weighted Average Number of Shares Outstanding, Diluted Weighted-average shares used in computing diluted net loss per common share (in shares) Condensed Consolidated Statements of Changes in Stockholders' Equity Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Treasury Stock, Common [Member] Accumulated Deficit [Member] Shares, Outstanding Balance (in shares) Balance (in shares) Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock in connection with exercise of options Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Exercised or vested Issuance of common stock in connection with exercise of options (in shares) Issuance of restricted stock Issuance of restricted stock (in shares) Debt Conversion, Converted Instrument, Amount Warrants issued with debt financing Forfeiture of restricted stock Forfeiture of restricted stock Stock Issued During Period, Shares, Restricted Stock Award, Forfeited Forfeiture of restricted stock (in shares) Issuance of common stock in public offering Issuance of common stock in public offering (in shares) Shares issued Compensation in respect of restricted stock granted to employees, directors and consultants Specific incremental costs directly attributable to a proposed or actual offering of securities. Offering Costs Offering costs Condensed Consolidated Statements of Cash Flows CASH FLOWS FROM OPERATING ACTIVITIES Adjustments to reconcile net loss to net cash used in operating activities: Share-based Compensation, Total Noncash stock compensation expense Total expense associated with the stock options Depreciation and amortization Depreciation and amortization Investment Income, Net, Amortization of Discount and Premium Amortization of premium (discount) on investment securities Amortization of Debt Issuance Costs Amortization of debt issuance costs Amortization of Lease Incentives Amortization of leasehold interest Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Noncash change in lease liability and right of use asset The change in fair value of notes payable during the period. Change In Fair Value Of Notes Payable Change in fair value of notes payable Changes in assets and liabilities: Increase (Decrease) in Inventories Increase in inventory Increase (Decrease) in Other Current Assets (Increase) decrease in other current assets Increase (Decrease) in Accounts Receivable (Increase) decrease in accounts receivable Increase (decrease) in accounts payable and accrued expenses Increase in other liabilities Decrease in lease liabilities Increase (Decrease) in Other Current Liabilities Increase in other current liabilities Decrease in deferred revenue Net Cash Provided by (Used in) Operating Activities, Continuing Operations Net cash used in operating activities CASH FLOWS FROM INVESTING ACTIVITIES The cash inflow associated with the maturities of held-to-maturity securities. Proceeds from maturity of short-term securities Amount of cash outflow (inflow) through acquisition (sale) of short-term held-to-maturity securities. Payments To Acquire Held To Maturity Securities Short Term Investment in held-to-maturity securities Payments to Acquire Property, Plant, and Equipment Purchases of PPE Net Cash Provided by (Used in) Investing Activities, Continuing Operations Net cash provided by (used in) investing activities CASH FLOWS FROM FINANCING ACTIVITIES Proceeds from (Repayments of) Secured Debt Payment of loan payable Proceeds from the exercise of warrants Proceeds from exercise of options Net proceeds Issuance of common stock, net Proceeds from Other Debt Proceeds from debt financings Payments of Financing Costs Financing costs paid Net Cash Provided by (Used in) Financing Activities, Continuing Operations Net cash (used in) provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT BEGINNING OF PERIOD Total cash, cash equivalents and restricted cash Reconciliation to amounts on condensed consolidated balance sheets: Reconciliation to amounts on condensed consolidated balance sheets: Restricted cash Interest Paid, Including Capitalized Interest, Operating and Investing Activities [Abstract] Cash paid for: Interest Paid, Excluding Capitalized Interest, Operating Activities Interest NONCASH TRANSACTIONS Amount of Accrued Financing Costs. Accrued Financing Costs Deferred financing costs Amount of Warrants Issued With Debt Financing. Warrants Issued With Debt Financing Warrants issued with debt financing ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block] ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES NET PRODUCT REVENUE PRODUCT REVENUE, NET NET PRODUCT REVENUE INVESTMENT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] INVESTMENT SECURITIES INVENTORY Inventory Disclosure [Text Block] INVENTORY FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] FAIR VALUE MEASUREMENTS STOCKHOLDERS' EQUITY Shareholders' Equity and Share-based Payments [Text Block] STOCKHOLDERS' EQUITY LOAN PAYABLE Long-term Debt [Text Block] LOAN PAYABLE LEASES Lessee, Operating Leases [Text Block] LEASES License Agreement [Abstract] LICENSE AGREEMENTS The entire disclosure for research, development, and License Agreement activities, including contracts and arrangements to be performed for others and with federal government. License Agreement Disclosure [Text Block] LICENSE AGREEMENTS RELATED PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] RELATED PARTY TRANSACTIONS SUBSEQUENT EVENTS Subsequent Events [Text Block] SUBSEQUENT EVENTS Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Disclosure of accounting policy for reporting when there is a substantial doubt about an entity's ability to continue as a going concern for a reasonable period of time (generally a year from the balance sheet date). Disclose: (a) pertinent conditions and events giving rise to the assessment of substantial doubt about the entity's ability to continue as a going concern for a reasonable period of time, (b) the possible effects of such conditions and events, (c) management's evaluation of the significance of those conditions and events and any mitigating factors, (d) possible discontinuance of operations, (e) management's plans (including relevant prospective financial information), and (f) information about the recoverability or classification of recorded asset amounts or the amounts or classification of liabilities. Liquidity and Capital Resources Revenue Recognition Receivable [Policy Text Block] Accounts Receivable Cost of Goods and Service [Policy Text Block] Cost of Product Revenue Inventory, Policy [Policy Text Block] Inventory Basic and Diluted Net Loss Per Common Share Net Loss Per Common Share Recently Issued Accounting Standards Summary of Significant Accounting Policies Dilutive securities excluded from computation Schedule of potentially dilutive securities Held-to-maturity Securities Schedule of investment securities Schedule of Inventory, Current [Table Text Block] Schedule of Inventory Change In Level Three Fair Value During Period Schedule of change in level three fair value during period Schedule of Share-based Compensation, Stock Options, Activity Summary of activity for stock options and restricted stock Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Schedule of compensation cost related to unvested awards No definition available. Schedule Of Long Term Debt Key Assumptions [Table] [Text Block] Schedule of key assumptions No definition available. Schedule Of Long Term Debt [Text Block] Schedule of loan payable Lease, Cost [Table Text Block] Schedule of lease cost Tabular disclosure for balance sheet classification of lease liabilities. Schedule Of Balance Sheet Classification Of Operating Lease [Table Text Block] Schedule of classification of lease liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Schedule of lease liability maturity Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Represents information pertaining to exclusive license agreement with LFB Biotechnologies, GTC Biotherapeutics and LFB/GTC LLC, all wholly-owned subsidiaries of LFB Group, relating to the development of ublituximab (the LFB License Agreement). BRIUMVI (Ublituximab) Represents the information pertaining to Neuraxpharm Pharmaceuticals, S.L. (Neuraxpharm) agreement. Neuraxpharm Agreement Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Liquidity and Capital Resources Cash, Cash Equivalents, and Short-term Investments Cash and cash equivalents, and investment securities The amount of a one-time, non-refundable payment made in accordance with commercialization agreements. License And Collaboration Agreements, One-Time, Non-Refundable Payment Amount of one-time, non-refundable payment upon contract execution Organization, Consolidation and Presentation of Financial Statements [Abstract] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met. Unvested Restricted Stock [Member] No definition available. Options [Member] Warrants [Member] Share Issuable Upon Note Conversion [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of diluted loss per share Potentially dilutive securities excluded from calculation Gross net accruals Gross Net Accruals Estimated amount of gross net accruals Investment Type [Axis] Investments [Domain] Short-term Investments [Member] Represents information pertaining to long term investments. Long-term investments [Member] Debt Security Category [Axis] Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain] Obligations of domestic governmental agencies [Member] Debt Securities, Held-to-maturity Amortized cost, as adjusted Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss Gross unrealized holding losses Estimated fair value Inventory [Line Items] Inventory Inventory, Raw Materials, Gross Raw Materials Inventory, Work in Process, Gross Work in Process Inventory, Finished Goods, Gross Finished Goods Cost of Goods and Services Sold Costs related to BRIUMVI Fair Value, by Balance Sheet Grouping [Table] Business Acquisition [Axis] Business Acquisition, Acquiree [Domain] No definition available. Manhattan and Ariston Pharmaceuticals Merger [Member] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value Measurements Notes Issued Debt Instrument, Term Debt instrument period Det instrument rate Debt Instrument, Convertible, Conversion Price Debt Instrument convertible conversion price Refers to the number of obligations. Number of Obligations Fair Value, Recurring and Nonrecurring [Table] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Measurements Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Balance at end of period Balance at beginning of period Amount of interest recognized during the period, arising from liabilities measured at fair value on a recurring basis using unobservable inputs (level 3). Interest accrued on face value of 5% Notes Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease) Change in fair value of Level 3 liabilities Preferred stock, shares authorized Preferred stock, par value Preferred stock, par value (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Warrant purchase price Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants issued Sale of Stock [Axis] Sale of Stock [Domain] Represents the information pertaining to 2022 At The Market (ATM). 2022 ATM [Member] Refers to the percent of commission of gross proceeds from the sale of common stock sold paid to agents. Common Stock, Commission Rate Percent of commission rate Sale of Stock, Number of Shares Issued in Transaction Shares sold Sale of Stock, Consideration Received on Transaction Net proceeds from offering Gross proceeds from offering Sale of Stock, Price Per Share Share price in offering Share Price Common share price on date of issuance Plan Name [Axis] Plan Name [Domain] Represents information pertaining to Amended and Restated 2012 Incentive Plan. Amended and Restated 2012 Incentive Plan [Member] Represents information pertaining to 2022 Incentive Plan. Incentive Plan 2022 [Member] Incentive Plan 2022 Statistical Measurement [Axis] Statistical Measurement [Domain] Maximum [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Approved shares available to be issued Number of shares authorized at full value awards for issuance under share-based payment arrangement. Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized, Full Value Awards Approved shares available for issue pursuant to full-value awards Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number Equity awards outstanding, beginning of year Restricted stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Equity awards outstanding, end of period Equity awards outstanding, beginning of year Options outstanding Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Number of additional shares that may be issued Other Inventory, Capitalized Costs, Gross Amount of stock-based compensation expense that was capitalized into inventory Restricted stock Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Expired or Forfeited Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Granted Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Exercised or vested Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Expired or Forfeited Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Expected weighted-average period in years of compensation cost to be recognized Debt Instrument [Axis] Debt Instrument, Name [Domain] Represents the loan agreement. Loan Agreement No definition available. Amended Loan Agreement No definition available. First Agreement Member Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number Warrants Issued Reflects the weighted average exercise price of warrants outstanding. Warrant Or Right Outstanding Weighted Average Exercise Price Weighted average exercise price of warrants Schedule of Long-term Debt Instruments [Table] Represents the information pertaining to term loan. Term Loan [Member] Scenario [Axis] Scenario [Domain] Represents the scenario when the prepayment occurs prior to the first anniversary of the first amendment effective date. Debt Instrument, Prepayment Occurs Prior To First Anniversary Of First Amendment Effective Date Represents the scenario when the prepayment occurs on or after first anniversary of the first amendment effective date. Debt Instrument, Prepayment Occurs On Or After The First Anniversary Of First Amendment Effective Date Variable Rate [Axis] Variable Rate [Domain] Prime Rate [Member] Minimum [Member] No definition available. Debt Instrument, Loan Tranche [Axis] No definition available. Debt Instrument, Loan Tranche [Domain] Refers to Debt Instrument, Tranche Three. Tranche Three Represents information pertaining to Debt Instrument Tranche ThreeA Advance Member. Tranche 3A Advance Represents information pertaining to Debt Instrument Tranche ThreeB Advance Member. Tranche 3B Advance Represents information pertaining to Debt Instrument Tranche ThreeC Advance Member. Tranche 3C Advance Refers to Debt Instrument, Tranche Four. Tranche Four Represents information pertaining to Debt Instrument Tranche Five [Member]. Tranche Five Debt Instrument [Line Items] Line of Credit Facility, Maximum Borrowing Capacity Maximum term loan facility Line of Credit, Current Amount of outstanding loan balance Amount drawn. Debt Instrument Draw Amount Amount of draw Number of advances. Number Of Advances Number of advances Refers to final payment fee as a percentage. Final Payment Fee, Percentage Final payment fee (as a percentage) Debt Instrument, Basis Spread on Variable Rate Spread added to rate ( as a percent) Paid in kind interest rate under the debt instrument agreement. Debt Instrument, Paid In Kind Interest Rate Paid in kind interest rate Amount drawn on first advance. Debt Instrument First Advance drawn Amount drawn on first advance Incremental amount to be withdrawn. Debt Instrument, Incremental Amount To Be Withdrawn Incremental amount Debt Instrument, Interest Rate, Stated Percentage Interest rate Number of additional advance under a tranche. Number Of Additional Advance Under a Tranche Additional advance under tranche Warrant coverage percentage. Warrant Coverage Percentage Percentage of final payment fee on other advances. Debt Instrument, Final Payment Fee On Other Advances Final payment Debt Instrument, Interest Rate, Effective Percentage Interest rate (as a percent) Refers to paid in kind interest rate. Paid-in-Kind Interest Rate Paid in kind interest rate Percentage of prepayment charge. Percentage Of Prepayment Charge Prepayment charge (as a percent) Warrant exercisable term. Warrant Exercisable Term Financing Interest Expense Financing expenses Debt Instrument, Unamortized Discount (Premium), Net Unamortized balance of debt Measurement Input Type [Axis] Measurement Input Type [Domain] Measurement Input, Exercise Price [Member] Measurement Input, Share Price [Member] Measurement Input, Price Volatility [Member] Measurement Input, Risk Free Interest Rate [Member] Measurement Input, Expected Term [Member] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price Exercise price Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Warrants and Rights Outstanding, Term Contractual term (in years) Other Long-term Debt Loan payable No definition available. End Of Term Fee Add: Accreted Liability of final payment fee No definition available. Long Term Debt Gross Loan payable, gross Unamortized Debt Issuance Expense Less: unamortized debt issuance costs Long-term Debt Loan payable Long term debt excluding principal payments Long Term Debt Excluding Principal Payments Total loan payable Related Party Transaction [Axis] Related Party Transaction [Domain] Office Agreement Member. Office Agreement [Member] Refers to the New Jersey lease. NJ Lease [Member] No definition available. NC Lease [Member] Restatement [Axis] Restatement [Domain] Restatement Adjustment It represents percentage of occupancy. Percentage Of Occupancy Area of Land Area of Land Operating Lease Initial Commitment Period Operating Lease Initial Commitment Period Operating lease initial commitment period Average Annual Rental Payments. Average Annual Rental Payments Operating Lease, Expense Rent expense Operating Lease, Liability Operating Lease Liability Total lease liability Remaining lease term of operating lease for lessee. Lessee Operating Lease Remaining Term Of Contract Remaining lease term Lessee, Operating Lease, Renewal Term Lease additional term Additional Collateral, Aggregate Fair Value Additional collateral pledged Operating Lease, Weighted Average Discount Rate, Percent Weighted-average discount rate for operating leases Operating Lease, Weighted Average Remaining Lease Term Weighted-average remaining operating lease term Operating Lease, Payments, Use Operating Lease, Cost Operating lease cost Lease, Cost Net lease cost Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year Remainder of 2023 Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months 2024 Lessee, Operating Lease, Liability, Payments, Due Year Two 2025 Lessee, Operating Lease, Liability, Payments, Due Year Three 2026 Lessee, Operating Lease, Liability, Payments, Due Year Four 2027 Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth year and thereafter. Lessee Operating Lease Liability Payments Due Year Five And Thereafter After 2028 Lessee, Operating Lease, Liability, Payments, Due Total lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: Interest Present value of lessee's discounted obligation for lease payments from operating lease at incremental borrowing rate. Operating Lease Liability, Incremental Borrowing Rate Present value of lease liabilities Represents information pertaining to to license the global rights to umbralisib, thereby entering into an exclusive licensing agreement (the Umbralisib License) UKONIQ (umbralisib) [Member] Represents amount received for sub license. Upfront Fee Received From Sub License Upfront fee Income taxes Revenue Represents the term after the first commercial sale. Term After First Commercial Sale Term after first commercial sale Represents the term of license. Term of License Term of license Deferred Revenue Amount of license revenue recorded during the period. License Revenue License revenue Current portion of deferred revenue Deferred Revenue, Current The amount of expenses incurred under the license and collaboration agreement. License And Collaboration Agreement, Expenses Incurred Expenses incurred Reflects potential milestone payments to be received upon achievement of pre-specified milestone. Additional Amount Receivable on Achievement of Pre-specified Milestones Additional payments on achievement of certain milestones Additional milestone-based payments on achievement of certain launch and commercial milestones Reflects potential milestone payments to be paid upon achievement of pre-specified milestone. Additional Amount Payable on Achievement of Pre-specified Milestones Potential milestones payable Accrued Royalties Accrued Royalties Royalty Expense Amount of royalty payable. Royalty Payable Royalty payable Schedule of Related Party Transactions, by Related Party [Table] No definition available. Shared Services Agreement [Member] Related Party Transaction [Line Items] Costs and Expenses, Related Party Incurred expenses Subsequent Event [Table] Subsequent Event [Line Items] Subsequent Event Reflects potential milestone payments to be received uponkey market commercial launch. Additional Payments Upon Key Market Commercial Launch Additional payment upon first key market commercial launch Royalty percentage on net product sales. Royalty Percentage on Net Product Sales Percentage of digit royalties on net product sales Agreement buyback period. Agreement Buyback Period